Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Ixabepilone (Primary)
- Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioma; Hepatic tumours; Leukaemia; Myeloid leukaemia; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 14 Mar 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Actual end date changed from Mar 2010 to Apr 2010 as reported by ClinicalTrials.gov.